glp-1 therapies May Benefit MPN And MDS Patients When fatigue shows up on

If prescribed, a provider will be just a message away for follow-ups, adjustments, and ongoing support

Advances in oral peptide delivery technologies and combination molecules targeting GLP-1, GIP, and glucagon receptors are expected to enhance therapeutic efficacy while reducing dependence on injectable formulations

doi: 10.1002/jnr.22565 167 McGovernSFHunterKHolscherC

The generic liraglutide includes a Boxed Warning to advise health care professionals and patients about the increased risk for thyroid C-cell tumors

Oral hypoglycemic agents allowable within 3 months prior to screening included biguanides, glycosidase inhibitors, sulfonylurea, glinides, thiazolidinediones, DPP-4 inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors

However, compounded drugs are not FDA-approved and may be associated with higher safety concerns and product quality issues